| Primary |
| Product Used For Unknown Indication |
55.8% |
| Antifungal Prophylaxis |
8.4% |
| Infection Prophylaxis |
4.2% |
| Urinary Tract Infection |
4.2% |
| Hiv Infection |
3.2% |
| Hiv Infection Cdc Category C3 |
3.2% |
| Atrial Fibrillation |
2.1% |
| Blood Pressure |
2.1% |
| Cellulitis |
2.1% |
| Oral Candidiasis |
2.1% |
| Oropharyngeal Pain |
2.1% |
| Prophylaxis Against Graft Versus Host Disease |
2.1% |
| Antibiotic Prophylaxis |
1.1% |
| Arthritis Bacterial |
1.1% |
| Ear Infection |
1.1% |
| Epididymitis |
1.1% |
| Gastritis Prophylaxis |
1.1% |
| Musculoskeletal Pain |
1.1% |
| Pharyngitis Bacterial |
1.1% |
| Pituitary Tumour Benign |
1.1% |
|
| Tubulointerstitial Nephritis |
25.0% |
| Idiopathic Thrombocytopenic Purpura |
7.1% |
| Visual Acuity Reduced |
7.1% |
| Bone Marrow Failure |
3.6% |
| International Normalised Ratio Increased |
3.6% |
| Petechiae |
3.6% |
| Proteinuria |
3.6% |
| Pulmonary Sepsis |
3.6% |
| Rash Generalised |
3.6% |
| Respiratory Acidosis |
3.6% |
| Respiratory Depression |
3.6% |
| Sleep Disorder |
3.6% |
| Stevens-johnson Syndrome |
3.6% |
| Syncope |
3.6% |
| Tongue Disorder |
3.6% |
| Toxic Epidermal Necrolysis |
3.6% |
| Tremor |
3.6% |
| Umbilical Malformation |
3.6% |
| Unresponsive To Stimuli |
3.6% |
| Vaginal Infection |
3.6% |
|
| Secondary |
| Hiv Infection |
20.5% |
| Antiretroviral Therapy |
12.2% |
| Product Used For Unknown Indication |
11.3% |
| Prophylaxis |
9.7% |
| Burkitt's Lymphoma |
6.8% |
| Drug Use For Unknown Indication |
5.8% |
| Hiv Test Positive |
3.3% |
| Prophylaxis Against Transplant Rejection |
3.3% |
| Chemotherapy |
3.1% |
| Chest Discomfort |
3.1% |
| Pneumocystis Jiroveci Pneumonia |
3.1% |
| Diarrhoea |
2.8% |
| Antifungal Prophylaxis |
2.6% |
| Pain In Extremity |
2.2% |
| Tuberculosis |
2.2% |
| Renal Transplant |
2.1% |
| Infection |
1.8% |
| Infection Prophylaxis |
1.6% |
| Acquired Immunodeficiency Syndrome |
1.3% |
| Diffuse Large B-cell Lymphoma |
1.3% |
|
| Vomiting |
22.6% |
| Urine Colour Abnormal |
9.7% |
| Weight Decreased |
9.7% |
| Renal Impairment |
6.5% |
| Transplant Rejection |
5.8% |
| White Blood Cell Count Decreased |
5.2% |
| Pyrexia |
4.5% |
| Solitary Kidney |
4.5% |
| Toxic Skin Eruption |
3.9% |
| Acute Myocardial Infarction |
3.2% |
| Sepsis |
3.2% |
| Tuberculosis |
3.2% |
| Hyponatraemia |
2.6% |
| Idiopathic Thrombocytopenic Purpura |
2.6% |
| Malaise |
2.6% |
| Pregnancy |
2.6% |
| Confusional State |
1.9% |
| Immune Reconstitution Syndrome |
1.9% |
| Neutropenia |
1.9% |
| Oropharyngeal Blistering |
1.9% |
|
| Concomitant |
| Product Used For Unknown Indication |
22.1% |
| Diffuse Large B-cell Lymphoma |
17.3% |
| Hiv Infection |
14.6% |
| Drug Use For Unknown Indication |
9.4% |
| Prophylaxis |
6.6% |
| Burkitt's Lymphoma |
3.7% |
| Antifungal Prophylaxis |
2.8% |
| Renal Transplant |
2.7% |
| Chronic Lymphocytic Leukaemia |
2.5% |
| Prophylaxis Of Nausea And Vomiting |
2.4% |
| Infection Prophylaxis |
2.0% |
| Sarcoma |
1.7% |
| Bone Marrow Conditioning Regimen |
1.7% |
| Rhabdomyosarcoma |
1.7% |
| Immunosuppression |
1.5% |
| Neoplasm Malignant |
1.5% |
| Prophylaxis Against Graft Versus Host Disease |
1.5% |
| Plasma Cell Myeloma |
1.5% |
| Tuberculosis |
1.4% |
| Graft Versus Host Disease |
1.4% |
|
| Malaise |
12.9% |
| Vomiting |
10.2% |
| Death |
7.2% |
| Thrombocytopenia |
6.0% |
| Weight Decreased |
6.0% |
| Spinal Fracture |
5.4% |
| Tuberculosis |
5.4% |
| Sepsis |
4.8% |
| Weight Increased |
4.8% |
| Second Primary Malignancy |
4.5% |
| Cardiac Disorder |
4.2% |
| Urinary Tract Infection |
4.2% |
| Rhabdomyolysis |
3.9% |
| Neutropenic Sepsis |
3.6% |
| Rash |
3.3% |
| Upper Respiratory Tract Infection |
3.0% |
| Muscular Weakness |
2.7% |
| Renal Failure Acute |
2.7% |
| Thrombotic Microangiopathy |
2.7% |
| White Blood Cell Count Decreased |
2.7% |
|
| Interacting |
| Atrial Fibrillation |
50.0% |
| Urinary Tract Infection |
50.0% |
|
| International Normalised Ratio Increased |
100.0% |
|
